{"id":"W7093303736","doi":"10.1210/jendso/bvaf149.2237","title":"OR31-04 Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Topline Results","year":2025,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Placebo; Adverse effect; Clinical endpoint; Antagonist; Phases of clinical research; Monoclonal antibody; Receptor antagonist; Antagonism","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009493463,0.000449221,0.0006016581,0.0002047514,0.0001972659,0.0007827105,0.0004198167,0.0007211049,0.008841787],"category_scores_gemma":[0.0005174766,0.0001392267,0.00101443,0.0002121571,0.0002807841,0.0004244535,0.0001857753,0.001732353,0.001751597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007364149,"about_ca_system_score_gemma":0.0008002128,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001291708,"about_ca_topic_score_gemma":0.003190602,"domain_scores_codex":[0.9997732,0.00007039912,0.00001416028,0.00002707962,0.00006621691,0.00004886912],"domain_scores_gemma":[0.9997509,0.00006499784,0.00005419933,0.00001967638,0.00003306381,0.00007718832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08249367,0.008176414,0.00666463,0.003038884,0.001153858,0.000451902,0.0002871099,0.002912589,0.07999945,0.001766347,0.07372705,0.7393281],"study_design_scores_gemma":[0.2469567,0.3464619,0.08020467,0.001340961,0.003034428,0.004548632,0.000278291,0.007434784,0.0498647,0.00302092,0.256671,0.0001830708],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8373013,0.07076875,0.004612178,0.006941484,0.0009531183,0.002528699,0.0153901,0.0009825416,0.06052175],"genre_scores_gemma":[0.9448069,0.01606164,0.003598442,0.003584164,0.0002907208,0.0009107459,0.011336,0.0001602322,0.01925118],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008841787,"threshold_uncertainty_score":0.02957869,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009867363082910592,"score_gpt":0.348483179231671,"score_spread":0.3386158161487604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}